Priapism is a urological emergency. The treatment for ischaemic priapism is usually cavernosal aspiration with or without cavernosal irrigation. Some patients may need surgical intervention -the various shunt procedures. We report a 21-year-old man with priapism secondary to chronic myeloid leukemia who needed a combined medical and surgical management. He underwent a spongiocavernosal shunt as well as cytoreductive chemotherapy to achieve complete detumescence. Therefore, cytoreductive chemotherapy is an adjunct in diffi cult to treat priapism associated with chronic myeloid leukemia
Leukemia, Myeloid

No abstract available.
Leukemia, Myeloid, Acute* ; Sarcoma, Myeloid*

A restrospective study carried out on 309 patients with chronic myelogenous leukemia treated from 1990 to 10/2000 showed that; -88 cases (28.3%) converted to the blast crisis. - 89.77% of these cases developed acute myeloblastic leukemia (AML) and 9.09% developed ALL.-The percentage of male and female were 55.68% and 44.31% - 45.45% of these converted cases occurred in the age group of 30-50. The youngest age was 10 months and the oldest age was : 72 years old. Mean of duration of the chronic phase was 2.5 years.
Leukemia, Myeloid, Chronic ; Leukemia, Myeloid, Chronic-Phase

No abstract available.
Leukemia, Myeloid, Acute*

No abstract available.
Humans ; Leukemia, Myeloid, Acute*

No abstract available.
Leukemia, Myeloid, Acute*

A retrospective study was carried out in 34 chronic myeloid leukemia patients, who were followed up from the beginning stage of the disease throughout natural history of the disease. The result shows the follows: the percentage of transformation into acute myeloid leukemia was 86.7%, the percentage of transformation into acute lymphocytic leukemia was 13.3%. The median length of chronic phase was 28.9 months. The median survival was 33.6 months (52.4% patients have survived more than 52 months). Main cause of death in chronic phase was emboli due to hyperleucocytic syndrome
Leukemia, Myeloid ; Hydroxyurea ; therapeutics

A patient with the chronic myeloid leukemia received the autologous stem cells transplantation of peripheral blood. The results have shown that the patient was responded well with the autograft, the graft grew early as estimation. The patient also responded completely with the treatment by Hydrea. The clinical and hematological signs were stable in the long-term. The complication during transplantation was mild. The total survival duration was 75 months.
Leukemia, Myeloid, Chronic ; therapeutics

88 patients with the chronic myeloid leukemia treated with Hydrea during 1/1999 - 12/2000. Most of them admitted to the center for hematology and blood transfusion in the conditions of very high leukocytosis and acute mortality risk due to cerebrovascular obstruction. Patients indicated by high dose of Hydrea in average duration of treatment of 6.5 (1.8 days. The treatment with Hydrea demonstrated that the survival duration of patients was lasted. The drug had fewer side effects. The treatment was not expensive. This is suitable for economic conditions of patients in Vietnam.
Leukemia, Myeloid, Chronic ; therapeutics

No abstract available.
Leukemia, Myeloid, Acute*